Edgewise Therapeutics Inc (EWTX)
$16.11
+0.46
(+2.94%)▲
Performance
- $15.60$16.33$16.11
3.17%
Downside
Day's Volatility :4.47%
Upside
1.35%
- $5.12$20.69$16.11
68.22%
Downside
52 Weeks Volatility :75.25%
Upside
22.14%
Returns
| Period | Edgewise Therapeutics Inc | |
|---|---|---|
3 Months | 2.42% | |
6 Months | 139.38% | |
1 Year | 107.07% | |
3 Years | -43.63% |
Highlights
Market Capitalization | 1.5B |
Book Value | $4.53 |
Earnings Per Share (EPS) | -1.57 |
Wall Street Target Price | 31.17 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -20.22% |
Return On Equity TTM | -30.1% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -112.8M |
Diluted Eps TTM | -1.57 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.72 |
EPS Estimate Next Year | -2.05 |
EPS Estimate Current Quarter | -0.43 |
EPS Estimate Next Quarter | -0.45 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 93.48%
Technicals Summary
Sell
Neutral
Buy
Edgewise Therapeutics Inc is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Edgewise Therapeutics Inc | 0.69% | 139.38% | 107.07% | -43.63% | -43.63% |
 Moderna, Inc. | -1.39% | 41.81% | -19.31% | -38.71% | 322.88% |
 Regeneron Pharmaceuticals, Inc. | -5.68% | 13.74% | 14.81% | 80.88% | 159.02% |
 Novo Nordisk A/s | -2.24% | 29.49% | 49.67% | 240.51% | 421.0% |
 Vertex Pharmaceuticals Incorporated | -3.67% | 10.39% | 20.74% | 84.71% | 129.52% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Edgewise Therapeutics Inc | 3.7 | NA | NA | -1.72 | -0.3 | -0.2 | NA | 4.53 |
Moderna, Inc. | 24.73 | NA | 0.0 | -6.77 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 26.13 | 26.13 | 1.46 | 45.02 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 48.36 | 48.36 | 2.4 | 3.34 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 29.17 | 29.17 | 0.53 | 16.75 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Edgewise Therapeutics Inc | Buy | $1.5B | -43.63% | 3.7 | 0.0% |
Moderna, Inc. | Buy | $41.3B | 322.88% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $99.6B | 159.02% | 26.13 | 30.14% |
Novo Nordisk A/s | Buy | $573.9B | 421.0% | 48.36 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $104.7B | 129.52% | 29.17 | 36.68% |
Institutional Holdings
Orbimed Advisors, LLC
15.65%FMR Inc
6.97%Viking Global Investors LP
6.61%Novo A/S
6.52%Deerfield Management Co
4.22%EcoR1 Capital, LLC
3.75%
Company Information
edgewise therapeutics is a biotechnology company focused on developing novel therapies for diseases involving skeletal muscle. the company is headquartered in boulder, co and received its series a financing from orbimed.
Organization | Edgewise Therapeutics Inc |
Employees | 88 |
CEO | Dr. Peter A. Thompson FACP, M.D. |
Industry | Healthcare |
Discover More
Acorda Therapeutics, Inc.
$16.11
+2.94%
Sight Sciences Inc
$16.11
+2.94%
Sangamo Therapeutics, Inc.
$16.11
+2.94%
Corbus Pharmaceuticals Holdings, Inc.
$16.11
+2.94%
Redhill Biopharma Ltd-sp Adr
$16.11
+2.94%
Fusion Pharmaceuticals Inc
$16.11
+2.94%
Geron Corporation
$16.11
+2.94%
Iradimed Corp
$16.11
+2.94%
Dbv Technologies S.a.
$16.11
+2.94%